Monte Rosa Therapeutics (NASDAQ:GLUE) Now Covered by Piper Sandler

Piper Sandler began coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE) in a report published on Monday, Price reports. The firm issued an overweight rating and a $40.00 price objective on the stock. Piper Sandler also issued estimates for Monte Rosa Therapeutics’ Q2 2021 earnings at ($0.47) EPS, Q3 2021 earnings at ($0.38) EPS, Q4 2021 earnings at ($0.41) EPS, FY2021 earnings at ($1.76) EPS, Q1 2022 earnings at ($0.44) EPS, Q2 2022 earnings at ($0.49) EPS, Q3 2022 earnings at ($0.51) EPS, Q4 2022 earnings at ($0.55) EPS and FY2022 earnings at ($1.99) EPS.

GLUE opened at $21.71 on Monday. Monte Rosa Therapeutics has a 1 year low of $18.01 and a 1 year high of $23.77.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers.

Featured Story: Gap Up Stocks

Receive News & Ratings for Monte Rosa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monte Rosa Therapeutics and related companies with's FREE daily email newsletter.